EISAI CO., LTD.

Insiders Eisai Co., Ltd.

Equities

4523

JP3160400002

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-05-02 am EDT			5-day change	1st Jan Change
6,545 ^JPY	-0.06%		+7.47%	-7.19%

Apr. 24	Biogen beats quarterly profit estimates, Alzheimer's drug sales jump	RE
Apr. 23	Alzheimer's drug adoption in US slowed by doctors' skepticism	RE

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Eisai exec who helped steer Alzheimer's drug approval to leave	23-07-11	RE
Eisai exec who helped steer Alzheimer's drug approval to retire in July	23-07-11	RE
Biogen splits R&D division ahead of key decision on Alzheimer's drug	23-01-05	RE
Scynexis Names Ivor Macleod CFO	22-10-25	MT
Biogen CEO to step down; drugmaker pulls back on Alzheimer's drug Aduhelm	22-05-03	RE
H3 Biomedicine Inc Appoints Richard Woodman to its Board of Directors	22-01-10	CI
Eisai Co., Ltd. Announces Executive Changes, Effective June 20, 2019	19-05-12	CI
Eisai Co., Ltd. Approves Appointment of Directors	17-06-21	CI
Eisai Appoints Avinash Desai as Vice President, Americas Oncology Medical Affairs, Oncology Business Group	16-04-25	CI
Eisai Co., Ltd. Appoints Paul Hawthorne Senior VP, US Commercial for its Neurology Group	16-04-25	CI
Eisai Co., Ltd. Announces the Retirement of Hajime Shimizu as Representative Corporate Officer, Effective March 31, 2016	16-03-01	CI
Eisai Co., Ltd. Appoints Eiichiro Suhara as Independent Director	15-06-19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Like the pros, access all the transcripts and spot the best opportunities before anyone else.

Unlock them now!

fermer